Eli Lilly (LLY) Offering Possible 13.64% Return Over the Next 3 Calendar Days

Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $138.00 short put and a strike $133.00 long put offers a potential 13.64% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $138.00 by expiration. The full premium credit of $0.60 would be kept by the premium seller. The risk of $4.40 would be incurred if the stock dropped below the $133.00 long put strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.

The RSI indicator is at 50.84 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Eli Lilly

Coronavirus Bear Market: All Stocks Are Under Quarantine, But Keep These Five Under Observation
Sat, 14 Mar 2020 12:00:37 +0000
In the coronavirus bear market, all stocks are under quarantine. But keep health care stocks Vertex, Biogen, Dexcom, Eli Lilly, Masimo under observation.

Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates
Fri, 13 Mar 2020 15:36:03 +0000
Lilly (LLY) signs deal with AbCellera to co-develop antibody therapies to treat COVID-19. AbbVie (ABBV) supports studies evaluating Kaletra for treating COVID-19.

Coronavirus Drug Development Efforts Pick Up Amid Sell-Off
Fri, 13 Mar 2020 15:01:03 +0000
Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.

The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals
Fri, 13 Mar 2020 14:53:12 +0000
The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus. I-Mab ADR (NASDAQ: IMAB)The Shanghai-based biopharma said Friday it is initiating the development pf TJM2 to treat cytokine storms in severe and critically ill patients caused by COVID-19. TJM2 is a neutralizing antibody against human granulocyte-macrophage colony stimulating factor, an important cytokine that plays a key role in acute and chronic inflammation.The company said it is awaiting FDA acceptance of an investigational new drug application. La Jolla Pharmaceutical Company (NASDAQ: LJPC)La Jolla said Friday that it is providing Giapreza in Italy for compassionate use in patients with septic shock associated with COVID-19. Giapreza was approved by the FDA in 2017 as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.It was later approved by the European Commission for treating refractory hypotension in adults with septic or other distributive shock.The drug, though approved by the EC, is not yet commercially available.Italian law allows authorized medicines for life-threatening and rare illnesses to be made available prior to commercial launch, according to La Jolla. Enanta Pharmaceuticals Inc (NASDAQ: ENTA)Enanta Pharma said Friday it has initiated a program to discover direct-acting antiviral drug candidates for treating patients infected with the coronavirus. The company said it is drawing upon its expertise in virology.The company is also screening compounds from its antiviral compound library for potential activity against COVID-19.See also: How Close Are Biotechs To Bringing A COVID-19 Treatment To Market? CAN FITE BIOPHARMA ADR REP 30 ORD (NYSE: CANF)Canadian biotech Can-Fite said Friday it is entering into a collaborative research agreement with the Lewis Katz School of Medicine at Templeton University, Philadelphia, to support research directed by Dr. Kamel Khalili, who is exploring the antiviral activity of piclidenoson on the coronavirus' viral load in a mammalian cell model system as a first step.Piclidenoson is Can-Fite's investigational Phase 3 asset currently being evaluated for rheumatoid arthritis and moderate-to-severe psoriasis.Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY)Roche said Friday that the FDA has issued an Emergency Use Authorization for the cobas SARS-CoV-2 Test.Eli Lilly And Co (NYSE: LLY)Lilly said Thursday that it's collaborating with AbCellera, a privately held company developing therapeutic antibodies, to co-develop antibody products for treating COVID-19.Meanwhile, Opko Health Inc. (NASDAQ: OPK) and Aytu Bioscience Inc (NASDAQ: AYTU) announced updates to their COVID-19 initiatives.Opko said Friday that its BioReference Labs subsidiary has begun accepting specimens for testing of COVID-19 from health care providers, clinics and health systems throughout the U.S.The company has announced a partnership with the New York State Department of Health for the first public drive-through testing facility on the East Coast. BioReference Labs is also planning to offer up to 5,000 tests a day at additional testing sites to be set up next week.Aytu announced the establishment Friday of a COVID-19 inquiry procedure to ensure the company adequately responds to inbound inquires from professionals and the public.The company said Tuesday that it clinched a distribution deal for a COVID-19 IgG/IgM Rapid Test.Biotech Price Action * La Jolla was rallying 8.92% to $4.15 * Can-Fite shares were rallying 5.26% to $1.40. * Lilly shares were advancing 5.09% to $132.44. * Opko Health was jumping 39.08% to $1.98. * Aytu was slipping 20.65% to $1.46. * OTC-listed Roche shares were up 7.77% at $38.43. Related Link: Inovio Continues To Rip Higher On Gates Foundation Funding For DNA Vaccine Delivery Device See more from Benzinga * The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO * The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Is Eli Lilly and Company (LLY) A Good Stock To Buy?
Fri, 13 Mar 2020 00:40:15 +0000
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.